On September 7, 2022 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies designed to treat immune-mediated diseases, reported that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in the following investor conferences in September (Press release, Aldeyra Therapeutics, SEP 7, 2022, View Source [SID1234619188]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 17th Annual BioPharma Conference (1×1 meetings only)
Wednesday, September 7, 2022
Boston, Mass.
H.C. Wainwright 24th Annual Global Investment Conference
Wednesday, September 14, 2022
New York, NY
Dr. Brady’s presentation at the H.C. Wainwright 24th Annual Global Investment Conference is scheduled to begin at 10:00 a.m. ET Wednesday, September 14, 2022. To view the live webcast, log in to the Investors & Media section of the Aldeyra website at View Source A replay will be available following the presentation and will be archived on the website for 90 days.